文献速递白血病造血干细胞移植与细胞治疗

采集时外周原始细胞与tisagenlecleucel治疗后生存的关系

Peripheral blasts at apheresis as a risk factor for survival after tisagenlecleucel in children and young adults.
PubMed 文献 · Blood Adv · 2026-01-01

本研究回顾性分析162例接受CD19 CAR-T治疗的儿童及年轻成人复发/难治B-ALL患者,评估采集时外周原始细胞对结局的影响。采集时有外周原始细胞者12个月EFS和OS较差,但该关联受输注时疾病负荷混杂,多变量分析中采集时原始细胞比例与死亡风险无显著独立关联。

要点

  • 采集时外周原始细胞与较差EFS/OS相关,但多变量分析未显示独立预后价值。
  • 28天缓解率在有无外周原始细胞组间相当。
  • 采集时原始细胞比例升高与死亡风险增加无显著独立关联。

核心结论

  • 采集时外周原始细胞与较差生存的关联在很大程度上受输注时疾病负荷影响。

研究设计与样本

  • 多中心回顾性队列研究,纳入儿童真实世界CAR联盟162例复发/难治B-ALL患者。

主要发现

  • 采集时有外周原始细胞者12个月EFS为27%,无外周原始细胞者为55%。
  • 采集时有外周原始细胞者12个月OS为55%,无外周原始细胞者为78%。
  • 28天缓解率在有无外周原始细胞组间相当。

临床怎么用

  • 采集时外周原始细胞可作为提示疾病负荷的指标,但不应单独作为独立预后因素解读。

局限性

  • 回顾性研究设计,采集时原始细胞与生存的关联受输注时疾病负荷混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Precursor B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood malignant neoplasm. Relapsed or refractory (R/R) B-ALL carries a dismal prognosis. CD19-specific chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment, yet relapse rates among responders remain high, with 40% to 50% experiencing relapse after therapy. This underscores the need for improved strategies to predict and prevent relapses after CAR T-cell therapy. This study reports the impact of peripheral blasts at the time of apheresis on outcomes in pediatric and young adult patients with R/R B-ALL treated with CD19-specific CAR T-cell therapy. A multi-institutional cohort of 162 patients from the Pediatric Real-World CAR Consortium was retrospectively analyzed. Key outcomes, such as day 28 response, event-free survival (EFS), and overall survival (OS), were evaluated based on the presence vs absence of peripheral blasts at apheresis. Although response at day 28 was comparable among peripheral blast groups in this cohort, the presence of peripheral blasts at apheresis was associated with inferior EFS (27% vs 55% at 12 months) and OS (55% vs 78% at 12 months). However, this association was confounded by disease burden at the time of infusion. In multivariable analysis, higher blast percentage at apheresis was not associated with an increased hazard of death (hazard ratio, 1.11; 95% confidence interval, 0.93-1.33; P = .25). These findings suggest that the association between peripheral blasts at apheresis and inferior survival is largely influenced by disease burden at infusion.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lyons KU, Miller KR, Deb A, et al. Peripheral blasts at apheresis as a risk factor for survival after tisagenlecleucel in children and young adults. Blood Adv. 2026. PMID: 42727020. doi:10.1182/bloodadvances.2025018654

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。